Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 13
Submit an article Journal homepage
230
Views
57
CrossRef citations to date
0
Altmetric
Drug Evaluation

Update on linezolid: the first oxazolidinone antibiotic

Mark H Wilcox Old Medical School, Department of Microbiology, Leeds General Infirmary, Leeds LS1 3EX, UK. [email protected]
Pages 2315-2326 | Published online: 12 Oct 2005

Bibliography

  • FRENCH G: Linezolid. Int. I Clia Piaci (2001) 55(1):59–63.
  • •An early overview of linezolid.
  • JONES RN, CROCO MA, KUGLER KC, PFALLER MA, BEACH ML: Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diego. Microbial. Infect. Dis. (2000) 37(2):115–125.
  • MORIN CA, HADLER JL: Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J. Infect. Dis. (2001) 184(8):1029–1034.
  • •Description of community-onset MRSA and the concept of healthcare-associated Infection.
  • NORRBY R: Linezolid - a review of the, first oxazolidinone. Expert, Opin. Pharmacother. (2001) 2(2):293–302.
  • •An early review of linezolid in the same Journal.
  • IOANAS M, LODE H: Linezolid in VAP by MRSA: a better choice? Intensive, Care Med. (2004) 30(3):343–346.
  • PERRY CM, JARVIS B: Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs (2001) 61(4):525–551.
  • •An early review of the activity of linezolid against Gram-positive bacteria.
  • STALKER DJ, JUNGBLUTH GL: Clinical pharmacokinetics, of linezolid, a novel oxazolidinone antibacterial. Pharmacokinet. (2003) 42(13):1129–1140.
  • •A review of the clinical pharmacokinetics of linezolid.
  • MOELLERING RC Jr: Linezolid: the first oxazolidinone, antimicrobial. Ann,. Intern. Med. (2003) 138(2):135–142.
  • •A recent review of linezolid.
  • WILCOX MH: Efficacy of linezolid versuscomparator therapies in Gram-positive infections. J. Antimicrob. Chemother. (2003) 51\(Suppl. 2):ii27-ii35. A, review of major clinical trials comparing the efficacy of linezolid with several comparator antibiotics in major indications of linezolid.
  • STEVENS DL, DOTTER B, MADARAS-KELLY K: A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti-infective Ther. (2004) 2(1):51–59.
  • ••A recent comprehensive review forlinezolid.
  • CRAVEN DE, PALLADINO R, MCQUILLEN DP: Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect. Dis. Clio. North Am. (2004) 18(4):939–962.
  • ••Guidelines for managing healthcare-associated pneumonia, by ATS and IDSA Joint committee. The role of linezolid is described in the article.
  • MEKA VG, GOLD HS: Antimicrobial resistance to linezolid. Clio. Infect. Dis. (2004) 39(7):1010–1015.
  • JONES RN, ANDEREGG TR, VNNE V, SADER HS, FRITSCHE TR: Trends in linezolid susceptibility patterns in 2002 and 2003: report from the worldwide ZAAPS program. ICAAC 2004. (2004) (Abstract).
  • HERRERO IA, ISSA NC, PATEL R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl. I Med. (2002) 346(11):867–869.
  • RAHIM S, PILLAI SK, GOLD HS, VENKATARAMAN L, INGLIMA K, PRESS RA: Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clio. Infect. Dis. (2003) 36(11):E146–E148.
  • WEIGELT J, ITANI K, STEVENS D, LAU W, DRYDEN M, KNIRSCH C: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. (2005) 49(6):2260–2266.
  • ••Report on the largest clinical trial to datecomparing the clinical efficacy of linezolid versus vancomycin in patients with cSSTI.
  • SHARPE JN, SHIVELY EH, POLK HC Jr: Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. (2005) 189(4):425–428.
  • WEIGELT J, KAAFARANI HM, ITANI KM, SWANSON RN: Linezolid eradicates, MRSA better than vancomycinfrom surgical-site infections. Am. J. Surg. (2004) 188(6):760–766.
  • •Comparing efficacy of linezolid versus vancomycin in surgical-site infection due to MRSA.
  • RUBINSTEIN E, CAMMARATA S, OLIPHANT T, WUNDERINK R, LINEZOLID NOSOCOMIAL PNEUMONIA STUDY GROUP: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clio. Infect. Dis. (2001) 32(3) :402–412.
  • •Comparing the efficacy and safety of linezolid versus vancomycin in nosocomial pneumonia.
  • WUNDERINK RG, CAMMARATA SK, OLIPHANT TH, KOLLEF MH, LINEZOLID NOSOCOMIAL PNEUMONIA STUDY GROUP: Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clio. Ther. (2003) 25(3):980–992.
  • •Continuation study of [19].
  • WUNDERINK RG, RELLO J, CAMMARATA SK, CROOS,-DABRERA RV, KOLLEF MH: Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 124(5):1789–1797.
  • •Retrospective analysis of the MRSA subpopulation in two studies described in [19].
  • KOLLEF MH, RELLO J, CAMMARATA, SK, CROOS,-DABRERA RV, WUNDERINK, RG: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. (2004) 30(3):388–394.
  • •Retrospective analysis of the ventilator-associated pneumonia subpopulation in two studies described in [19, 20].
  • WILCOX M, NATHWANI D, DRYDEN M: Linezolid compared with teicoplanin, for the treatment of suspected or proven Gram-positive infections. Antimicrob. Chemother. (2004) 53(2)335–344.
  • •Comparing the efficacy and safety of linezolid versus teicoplanin for the treatment of Gram-positive infections.
  • LIVERMORE DM: Bacterial resistance: origins, epidemiology, and impact. Gila Infect. Dis. (2003) 36\(Suppl. 1):S11–S23.
  • RUBIN RJ, HARRINGTON CA, POON A, DIETRICH K, GREENE JA, MOIDUDDIN A: The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. (1999) 5(1):9–17.
  • The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannil and Pseudmonas aeruginosa on length of hospital stay. Infect. Control Hosp. Epidemiol (2002) 23(2):106–108.
  • CARBON C: Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. I, Antimicrob. Chemother. (1999) 44(Suppl. A):31–36.
  • ABRAMSON MA, SEXTON DJ: Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect. Control Hasp. Epidemiol (1999) 20(6):408–411.
  • LI Z, WILLKE RJ, PINTO LA et al: Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy (2001) 21(3):263–274.
  • •Comparing the health-economic outcomes of linezolid versus vancomycin.
  • WEIGELT J, ITANI K, LAU W, LI J: Linezolid reduces length of stay when compared to vancomycin for complicated skin and soft tissue infections due to Suspected or Proven Methicillin-resistant Staphylococcus aureus: Results From a Randomized Trial. 41st Annual Meeting of the Infectious Diseases Socieh, of America, San, Diego, CA, USA (2003) (Poster 315).
  • SORENSEN S, HOLLENBEAK C, LIU L, BAKER T, ITANI K: Cost-effectiveness of linezolid versus vancomycin in the treatment of complicated skin and soft-tissue infection due to suspected or proven methicillin-resistant Staphylococcus aureus. 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, USA (2004) (Poster 503).
  • NATHWANI D, LI JZ, BALAN DA et al: An, economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int. J. Antimicrob. Agents. (2004) 23(4):315–324.
  • •Comparing the health effectiveness of linezolid versus vancoteicoplanin.
  • PEA F, BROLLO L, VIALE P, PAVAN F, FURLANUT M: Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose." Antimicrob. Chemother. (2003) 51(4):971–975.
  • RUBINSTEIN E, ISTURIZ R, STANDIFORD HC et al: Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob. Agents Chemother. (2003) 47(6):1824–1831.
  • ••Safety assessment for linezolid.
  • ZYVOX package insert: Pfizer Inc, New York, NY, USA. (2005).
  • RAYNER CR, BADDOUR LM, BIRMINGHAM MC, NORDEN C, MEAGHER AK, SCHENTAG JJ: Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection (2004) 32(1):8–14.
  • BRESSLER AM, ZIMMER SM, GILMORE JL, SOMANI J: Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. (2004) 4(8):528–531.
  • KOPTERIDES P, PAPADOMICHELAKIS E, ARMAGANIDIS A: Linezolid use associated with lactic acidosis. Scand. I Infect. Dis. (2005) 37(2):153–154.
  • APODACA AA, RAKITA RM: Linezolid-induced lactic acidosis. N Engl. ". Med. (2003) 348(1):86–87.
  • NASRAWAY SA, SHORR AF, KUTER DJ, O'GRADY N, LE VH, CAMMARATA SK: Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin. Infect. Dis. (2003) 37(12):1609–1616.
  • •Comparing the rates of thrombocytopoenia, associated with linezolid and vancomycin.
  • SPELLBERG B, Y00 T, BAYER AS: Reversal, of linezolid-associated cytopenias, but not peripheral neuropathy, by administration, of vitamin B6. Antimicrob. Chemother. (2004) 54:832–835
  • JONES SL, ATHAN E, O'BRIEN D: Serotonin syndrome due to co-administration of linezolid and venlafaxine. Antimicrob. Chemother. (2004) 54(1):289–290.
  • WIGEN CL, GOETZ MB: Serotonin syndrome and linezolid. Clin Infect Dis. (2002) 34(12):1651–1652.
  • COSGROVE SE, SAKOULAS G, PERENCEVICH EN et al: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. (2003) 36:53–59.
  • MOSDELL DM, MORRIS DM, VOLTURA A et al: Antibiotic treatment for surgical peritonitis. Ann. Surg. (1991) 214:543–549.
  • IBRAHIM EH, SHERMAN G, WARD S, FRASER VJ, KOLLEF MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 118:146–55.
  • REACHER MH, SHAH A, LIVERMORE, DM et al.: Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Br. Med. I (2000) 320(7229):213–216.
  • SMITH TL, PEARSON ML, WILCOX, KR et al: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl. J. Med. (1999) 340(7):493–501.
  • •Case report of glycopeptide-intermediate S. aureus
  • AUCKEN HM, WARNER M, GANNER M et al.: Twenty months of screening for glycopeptide-intermediate Staphylococcus, aureus. Antimicrob.Chemother. (2000) 46(4):639–640.
  • CDC: Staphylococcus aureus resistant to vancomycin - United States. MMWR Morb. Mortal. Wkly Rep. (2004) 51:565–567.
  • GUERIN F, BUU-HOI A, MAINARDI JL et al: Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. Chi]. Microbial. (2000) 38(8):2985–2988.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Vancomycin-resistant Staphylococcus aureus- New, York, 2004. MMWR Morb. Mortal. Wkly Rep. (2004) 53(15):322–323.
  • WHITENER CJ, PARK SY, BROWNE FA et al.: Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. (2004) 38(8):1049–1055.
  • KRCMERY V Jr, SPANIK S, TRUPL J: First report of vancomycin-resistant Streptococcus mitis bacteremia in a leukemic patient after prophylaxis with quinolones and during treatment with vancomycin../. Cheinother. (1996) 8(4):325–326.
  • POYART C, PIERRE C, QUESNE G, PRON B, BERCHE P, TRIEU-CUOT P: Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob. Agents Cheinother. (1997) 41(1):24–29.
  • STINEAR TP, OLDEN DC, JOHNSON PD, DAVIES JK, GRAYSON ML: Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet (2001) 357(9259):855–856.
  • DOMINGO MC, HULETSKY A, BERNAL A et al: Characterization of a Tn5382-like transposon containing the vanB2 gene cluster in a Clostridium strain isolated from human faeces. Antimicrob,. Cheinother. (2005) 55(4):466–474.
  • SALYERS AA, GUPTA A, WANG Y: Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol. (2004) 12(9):412–416.
  • WYSOCKI M, DELATOUR F, FAURISSON F et al: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Cheinother. (2001) 45:2460–2467.
  • PEA F, BROLLO L, VIALE P, PAVAN F,FURLANUT M: Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J. Antimicrob. Cheinother (2003) 51:971–975.
  • DARLEY ES, MACGOWAN AP: The use and therapeutic drug monitoring of teicoplanin in the UK. Clin. Microbiol Infect. (2004) 10:62–69.
  • SAIMAN L, GOLDFARB J, KAPLAN SA et al: Safety and tolerability of linezolid in children. Pediatr. Infect. Dis. J. (2003) 2 2 (Suppl. 9):5193–5200.
  • BRIER ME, STALKER DJ, ARONOFF, GR et al: Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob. Agents Cheinother. (2003) 47(9):2775–2780.
  • STEIN GE, SCHOOLEY SL, PELOQUIN, CA et al: Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann. Pharinacother. (2005) 39(3):427–432.
  • LIPSKY BA, ITANI K, NORDEN C, LINEZOLID DIABETIC FOOT INFECTIONS STUDY GROUP: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/ amoxicillin-clavulanate. Clin. Infect. Dis. (2004) 38(1):17–24.
  • •Comparing the efficacy and safety of linezolid versus ampicillin sulbactam/ amoxicillin-davulanate. Website,

Websites

  • http://www.bsac.org.ukg content_display.cfm?cit_id=331 Guidelines for the prophylaxis and treatment of meticillin resistant, Staphylococcus aureus (MRSA) infections in the United Kingdom (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.